Modulation of tumor immunity by therapeutic monoclonal antibodies. - Wikidata - wikimedia - TriplyDB

Modulation of tumor immunity by therapeutic monoclonal antibodies.

Modulation of tumor immunity by therapeutic monoclonal antibodies.

http://www.wikidata.org/entity/Q37832438

about

Overview of Methods for Overcoming Hindrance to Drug Delivery to Tumors, with Special Attention to Tumor Interstitial Fluid Reprogramming urokinase into an antibody-recruiting anticancer agent.Trial Watch: Monoclonal antibodies in cancer therapy Cancer risks related to low-level RF/MW exposures, including cell phones.Designing effective vaccines for colorectal cancer.Impact of Depleting Therapeutic Monoclonal Antibodies on the Host Adaptive Immunity: A Bonus or a Malus?IL-2- or IL-15-activated NK cells enhance Cetuximab-mediated activity against triple-negative breast cancer in xenografts and in breast cancer patients.The ultimate goal of curative anti-cancer therapies: inducing an adaptive anti-tumor immune response.Anti-CD20 therapy induces a memory Th1 response through the IFN-γ/IL-12 axis and prevents protumor regulatory T-cell expansion in mice.Trial watch: Monoclonal antibodies in cancer therapy

P2860

Q26799981-3B4DB68D-B59F-4088-8B40-467B412A859D Q35785499-09EF2B3B-423F-4F90-B821-0D84B4F57880 Q36038408-97DA23C7-E860-4D7D-9430-ED0E7D21BF48 Q38074183-36DEE86A-F9A1-4086-8081-FE92CC0D09F0 Q38260051-CF27DFCD-9F84-4E28-9903-A51EFFC1748D Q38601426-1667C38D-DEBB-4297-8303-CB68701AE52C Q39259470-8705E0F3-1B6C-49C1-B6FD-BCA210873B6E Q42143991-D678FDBB-2508-44C8-AFE0-19B3C1A8EBC9 Q50780383-C69B1E51-A0C5-4F42-9D8E-D5FE5D669745 Q56932681-88DBACC0-C3F6-4A49-853C-7F4D7FFEB630

P2860

Modulation of tumor immunity by therapeutic monoclonal antibodies.

http://www.wikidata.org/entity/Q37832438

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on March 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Modulation of tumor immunity by therapeutic monoclonal antibodies.

@en

Modulation of tumor immunity by therapeutic monoclonal antibodies.

@nl

type

label

Modulation of tumor immunity by therapeutic monoclonal antibodies.

@en

Modulation of tumor immunity by therapeutic monoclonal antibodies.

@nl

prefLabel

Modulation of tumor immunity by therapeutic monoclonal antibodies.

@en

Modulation of tumor immunity by therapeutic monoclonal antibodies.

@nl

P1433

Q37832438-4A22F6BC-9776-4CB1-AB8F-4960320EA672

P1476

Q37832438-5F6DA41A-7D6B-43E4-AE7F-ED0BB1D577BE

P2093

Q37832438-23C9DB42-5A84-47B3-9219-182C972D3B06

Q37832438-D007113A-BDDA-4B91-A380-C7E95A971640

P2860

Q37832438-00863ED0-6FBF-49F9-BDD7-6609D90F071F

Q37832438-0340A346-2185-4B83-B0C4-60B74F5F4F30

Q37832438-0356BAF6-CCD5-49C2-A3FE-79EBA0829783

Q37832438-076AAFC0-1DD9-4FD7-98B0-42C3FC14760C

Q37832438-0960A1F8-764D-4FEA-BB0C-6E6AE7C73665

Q37832438-0DFCB784-90C2-42BE-A849-0BD57B435174

Q37832438-0EAEBAA6-FA37-427E-AC61-7172CC22B571

Q37832438-1077629C-E202-4DD8-9830-F3290042023C

Q37832438-131FE06C-2739-493B-ADF6-F226AC474534

Q37832438-160CE5D1-EDC3-47D6-9972-963DD0F312AA

P2888

Q37832438-46061816-C790-4C6A-9CF2-8D30D53494DE

P304

Q37832438-01139244-BA54-40BA-9F77-B8A514066833

P31

Q37832438-27911BF6-48F4-46E6-B428-D061681EB38A

P356

Q37832438-EC6094E5-A316-4948-9845-D3586984701B

P433

Q37832438-C5465B73-1195-4B9F-80C5-D8F98D05ABE4

P478

Q37832438-74BC7926-AE50-43CF-B0B1-0EBCAE55923A

P577

Q37832438-91972B00-0EEF-4BE1-820B-BD01D9199515

P698

Q37832438-7CDB5535-9C6A-4F43-9FBF-FF361758B980

P921

Q37832438-32B72351-BDA9-4460-AF2B-C85E159C2C1A

P356

S10555-011-9282-3

P1433

Cancer and Metastasis Reviews

P1476

Modulation of tumor immunity by therapeutic monoclonal antibodies.

@en

P2093

Jean-Luc Teillaud

http://www.w3.org/2001/XMLSchema#string

Riad Abès

http://www.w3.org/2001/XMLSchema#string

P2860

A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening

Continuous cultures of fused cells secreting antibody of predefined specificity

Dendritic cells and the control of immunity

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

Tumor regression in cancer patients by very low doses of a T cell-engaging antibody

Fcgamma receptors as regulators of immune responses

Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group.

Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma.

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.

P2888

s10555-011-9282-3

P304

111-124

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10555-011-9282-3

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P577

2011-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21267767

http://www.w3.org/2001/XMLSchema#string

P921